Pancreatic Cancer Research

ResearcherAalborg University HospitalActive in the last 2 years

Mogens Tornby Stender

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-7442-3653; OpenAlex author ID A5107467141, A5108270542. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Characteristics, Prognosis and Reasons for Opting-Out of Treatment in Patients with Untreated Pancreatic Cancer. First author DOI 10.3390/curroncol33020116↗
  2. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1097/eus.0000000000000156↗
  3. Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. Co-author DOI 10.1016/j.isci.2024.111026↗
  4. Impact of para aortic lymph node removal on survival following resection for pancreatic adenocarcinoma. Co-author DOI 10.1186/s12893-023-02123-2↗
  5. Long-Term Outcomes of Venous Resections in Pancreatic Ductal Adenocarcinoma Patients: A Nationwide Cohort Study. Co-author DOI 10.1097/as9.0000000000000219↗
  6. Irreversible electroporation of pancreatic cancer - Effect on quality of life and pain perception. Co-author DOI 10.1016/j.pan.2021.04.011↗
  7. Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer-Results from a Prospective Cohort. Co-author DOI 10.3390/cancers13122862↗
  8. Imaging response evaluation after local ablative treatments in locally advanced pancreatic cancer: an expedited systematic review. First author DOI 10.1016/j.hpb.2020.04.011↗
  9. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility. First author DOI 10.1080/00365521.2019.1575465↗
  10. D-Dimer predicts prognosis and non-resectability in patients with pancreatic cancer: a prospective cohort study. Co-author DOI 10.1097/mbc.0000000000000559↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ole Thorlacius‐Ussing · 6 shared papers, 2016–2024 · strength 0.86
  2. Morten Bækbo Ladekarl · 2 shared papers, 2024–2026 · strength 0.83
  3. Rasmus Virenfeldt Flak · 5 shared papers, 2019–2024 · strength 0.77
  4. Carsten Palnæs Hansen · 3 shared papers, 2022–2025 · strength 0.61
  5. Sönke Detlefsen · 2 shared papers, 2024–2025 · strength 0.45
  6. Claus Wilki Fristrup · 2 shared papers, 2022–2025 · strength 0.42
  7. Jan Henrik Storkholm · 2 shared papers, 2022–2023 · strength 0.36
  8. Martin Sillesen · 2 shared papers, 2022–2023 · strength 0.36
  9. Stefan Kobbelgaard Burgdorf · 2 shared papers, 2022–2023 · strength 0.36
  10. Lars Jelstrup Petersen · 2 shared papers, 2020–2021 · strength 0.30
  11. Frank Viborg Mortensen · 1 shared paper, 2025 · strength 0.26
  12. Peter Vilmann · 1 shared paper, 2025 · strength 0.26
  13. Jakob Kirkegård · 1 shared paper, 2025 · strength 0.26
  14. Bojan Kovacevic · 1 shared paper, 2025 · strength 0.26
  15. Michael Bau Mortensen · 1 shared paper, 2025 · strength 0.26
  16. Susy Shim · 1 shared paper, 2024 · strength 0.20
  17. Sophie Louise Gisela Kollbeck · 1 shared paper, 2023 · strength 0.19
  18. Stine Dam Henriksen · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.